Caley Castelein, Director at Tourmaline Bio, Inc. (TRML), bought 20,000 shares at $12.07 ($281K) on 2023-10-25, disclosed to the SEC on 2023-10-27.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.07 | 4,200 | $51K | 18.1% |
| 2 | $14.55 | 15,800 | $230K | 81.9% |
| Total | $14.03 avg | 20,000 | $281K | 100% |
| Filing → |
| AADI | BUY | 2021-08-30 | $6.8M | — | Filing → |
| PrivateAerpio Pharmaceuticals, Inc. | BUY | 2017-03-17 | $2.0M | — | Filing → |